473 related articles for article (PubMed ID: 19130459)
21. Apocrine carcinoma as triple-negative breast cancer: novel definition of apocrine-type carcinoma as estrogen/progesterone receptor-negative and androgen receptor-positive invasive ductal carcinoma.
Tsutsumi Y
Jpn J Clin Oncol; 2012 May; 42(5):375-86. PubMed ID: 22450930
[TBL] [Abstract][Full Text] [Related]
22. [Invasive lobular carcinoma of basal-like subtype of breast: a clinicopathologic analysis].
Zhang LY; Gao LX; Liu G; Yang GZ; Cheng J; Ding HY
Zhonghua Bing Li Xue Za Zhi; 2013 Sep; 42(9):599-603. PubMed ID: 24314245
[TBL] [Abstract][Full Text] [Related]
23. Comparisons of p53, KI67 and BRCA1 expressions in patients with different molecular subtypes of breast cancer and their relationships with pathology and prognosis.
Li Y; Zhang X; Qiu J; Pang T; Huang L; Zeng Q
J BUON; 2019; 24(6):2361-2368. PubMed ID: 31983107
[TBL] [Abstract][Full Text] [Related]
24. RERG (Ras-like, oestrogen-regulated, growth-inhibitor) expression in breast cancer: a marker of ER-positive luminal-like subtype.
Habashy HO; Powe DG; Glaab E; Ball G; Spiteri I; Krasnogor N; Garibaldi JM; Rakha EA; Green AR; Caldas C; Ellis IO
Breast Cancer Res Treat; 2011 Jul; 128(2):315-26. PubMed ID: 20697807
[TBL] [Abstract][Full Text] [Related]
25. [Relationship between breast cancer molecular subtypes with clinicopathological characteristics and prognosis].
Lin M; Chen ZQ; Bao Y; Li Q; Du ZG; Xu ZD; Tang F
Zhonghua Bing Li Xue Za Zhi; 2010 Jun; 39(6):372-6. PubMed ID: 21055152
[TBL] [Abstract][Full Text] [Related]
26. Immunohistochemical analysis of ER, PR, Her2 and CK5/6 in infiltrative breast carcinomas in Indian patients.
Munjal K; Ambaye A; Evans MF; Mitchell J; Nandedkar S; Cooper K
Asian Pac J Cancer Prev; 2009; 10(5):773-8. PubMed ID: 20104967
[TBL] [Abstract][Full Text] [Related]
27. Triple negative breast cancer: a study from the point of view of basal CK5/6 and HER-1.
Pintens S; Neven P; Drijkoningen M; Van Belle V; Moerman P; Christiaens MR; Smeets A; Wildiers H; Vanden Bempt I
J Clin Pathol; 2009 Jul; 62(7):624-8. PubMed ID: 19561231
[TBL] [Abstract][Full Text] [Related]
28. Breast cancer molecular class ERBB2: preponderance of tumors with apocrine differentiation and expression of basal phenotype markers CK5, CK5/6, and EGFR.
Bhargava R; Beriwal S; Striebel JM; Dabbs DJ
Appl Immunohistochem Mol Morphol; 2010 Mar; 18(2):113-8. PubMed ID: 19801938
[TBL] [Abstract][Full Text] [Related]
29. Determination of HER2 phosphorylation at tyrosine 1221/1222 improves prediction of poor survival for breast cancer patients with hormone receptor-positive tumors.
Frogne T; Laenkholm AV; Lyng MB; Henriksen KL; Lykkesfeldt AE
Breast Cancer Res; 2009; 11(1):R11. PubMed ID: 19239686
[TBL] [Abstract][Full Text] [Related]
30. Breast cancer subtypes identified by the ER, PR and HER-2 status in Thai women.
Chuthapisith S; Permsapaya W; Warnnissorn M; Akewanlop C; Sirivatanauksorn V; Prasarttong Osoth P
Asian Pac J Cancer Prev; 2012; 13(2):459-62. PubMed ID: 22524806
[TBL] [Abstract][Full Text] [Related]
31. Patterns of recurrence in the basal and non-basal subtypes of triple-negative breast cancers.
Nofech-Mozes S; Trudeau M; Kahn HK; Dent R; Rawlinson E; Sun P; Narod SA; Hanna WM
Breast Cancer Res Treat; 2009 Nov; 118(1):131-7. PubMed ID: 19189211
[TBL] [Abstract][Full Text] [Related]
32. The prognostic significance of WWOX expression in patients with breast cancer and its association with the basal-like phenotype.
Wang X; Chao L; Ma G; Chen L; Zang Y; Sun J
J Cancer Res Clin Oncol; 2011 Feb; 137(2):271-8. PubMed ID: 20401669
[TBL] [Abstract][Full Text] [Related]
33. Immunohistochemical profile of breast cancer patients at a tertiary care hospital in South India.
Ambroise M; Ghosh M; Mallikarjuna VS; Kurian A
Asian Pac J Cancer Prev; 2011; 12(3):625-9. PubMed ID: 21627355
[TBL] [Abstract][Full Text] [Related]
34. Expression of DNA methylation marker of paired-like homeodomain transcription factor 2 and growth receptors in invasive ductal carcinoma of the breast.
Wan Abdul Rahman WF; Fauzi MH; Jaafar H
Asian Pac J Cancer Prev; 2014; 15(19):8441-5. PubMed ID: 25339043
[TBL] [Abstract][Full Text] [Related]
35. [Loss of fragile histidine triad expression and metastasis in breast cancer].
Zhao P; Li XY; Chen LZ
Ai Zheng; 2002 Jun; 21(6):668-70. PubMed ID: 12452072
[TBL] [Abstract][Full Text] [Related]
36. Immunohistochemical analysis of ER, PR, HER-2, CK 5/6, p63 and EGFR antigen expression in medullary breast cancer.
Matkovic B; Juretic A; Separovic V; Novosel I; Separovic R; Gamulin M; Kruslin B
Tumori; 2008; 94(6):838-44. PubMed ID: 19267102
[TBL] [Abstract][Full Text] [Related]
37. Breast Cancer Molecular Subtypes Defined by ER/PR and HER2 Status: Association with Clinicopathologic Parameters in Ivorian Patients.
Effi AB; Aman NA; Koui BS; Koffi KD; Traore ZC; Kouyate M
Asian Pac J Cancer Prev; 2016; 17(4):1973-8. PubMed ID: 27221883
[TBL] [Abstract][Full Text] [Related]
38. Basal cytokeratin as a potential marker of low risk of invasion in ductal carcinoma in situ.
Aguiar FN; Mendes HN; Cirqueira CS; Bacchi CE; Carvalho FM
Clinics (Sao Paulo); 2013 May; 68(5):638-43. PubMed ID: 23778411
[TBL] [Abstract][Full Text] [Related]
39. Clinicopathological characteristics of triple negative breast cancer at a tertiary care hospital in India.
Dogra A; Doval DC; Sardana M; Chedi SK; Mehta A
Asian Pac J Cancer Prev; 2014; 15(24):10577-83. PubMed ID: 25605142
[TBL] [Abstract][Full Text] [Related]
40. Variations in tumor marker levels in metastatic breast cancer patients according to tumor subtypes.
Kos T; Aksoy S; Sendur MA; Arik Z; Civelek B; Kandemir N; Ozdemir NY; Zengin N; Altundag K
J BUON; 2013; 18(3):608-13. PubMed ID: 24065471
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
